Literature DB >> 10982066

Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

R Borrow1, A J Fox, P C Richmond, S Clark, F Sadler, J Findlow, R Morris, N T Begg, K A Cartwright.   

Abstract

The induction of immunological memory to serogroup A and C polysaccharides in UK infants immunized with three doses of a meningococcal A/C oligosaccharide CRM197 conjugate vaccine was investigated. Forty UK infants vaccinated previously with three doses of a meningococcal A/C oligosaccharide-CRM197 conjugate vaccine at 2, 3 and 4 months of age, were revaccinated at a mean age of 145.6 weeks with either a 10 or 50 microg dose of licensed meningococcal A/C polysaccharide vaccine. Serogroup-specific antibody and serum bactericidal antibody (SBA) responses were measured by enzyme-linked immunosorbent assay and serum bactericidal assays, respectively. Following challenge, anti-serogroup A and C polysaccharide antibody levels rose from pre-booster geometric mean concentrations (GMC) of 3.1 and 2.1 microg/ml respectively to 19.6 and 21.0 microg/ml 1 month post-booster. Serum bactericidal antibody geometric mean titres (GMTs) for serogroups A and C increased 156- and 113-fold from 2.1 and 7.1 pre-booster respectively to 327.4 and 800.7 post-booster. A serogroup A control group of 45 children received a 10 microg dose of licensed meningococcal A/C polysaccharide vaccine (with no prior history of serogroup A vaccination) had serogroup A SBA GMTs of 2.3 pre-vaccination rising to 8 post-vaccination with corresponding GMCs of 0.8 and 10.8 microg/ml. These rises in SBA following serogroup A/C conjugate vaccination are indicative of immunological priming.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982066      PMCID: PMC2810928          DOI: 10.1017/s0950268899003787

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

1.  Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?

Authors:  Theodore F Tsai; Ray Borrow; Hanspeter E Gnehm; Bernard Vaudaux; Ulrich Heininger; Daniel Desgrandchamps; Christoph Aebi; Paul Balmer; Ronald D Pedersen; Bernard Fritzell; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2006-08

2.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

3.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Priming for immunologic memory in adults by meningococcal group C conjugate vaccination.

Authors:  David M Vu; Alberdina W de Boer; Lisa Danzig; George Santos; Bridget Canty; Betty M Flores; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2006-06

5.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.

Authors:  Shannon L Harris; W James King; Wendy Ferris; Dan M Granoff
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Authors:  Shannon L Harris; Adam Finn; Dan M Granoff
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

9.  Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Authors:  Milagritos D Tapia; Helen Findlow; Olubukola T Idoko; Marie-Pierre Preziosi; Prasad S Kulkarni; Godwin C Enwere; Cheryl Elie; Varsha Parulekar; Samba O Sow; Fadima Cheick Haidara; Fatoumata Diallo; Moussa Doumbia; Adebayo K Akinsola; Richard A Adegbola; Beate Kampmann; Julie Chaumont; Lionel Martellet; Elisa Marchetti; Simonetta Viviani; Yuxiao Tang; Brian D Plikaytis; F Marc LaForce; George Carlone; Ray Borrow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.